Craig-Hallum initiated coverage of Atossa Therapeutics (ATOS) with a Buy rating and $4 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics Reports Q1 2025 Financial Results
- Atossa Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
- Atossa Therapeutics reports results from Phase 2 EOP sub-study
- Optimistic Buy Rating for Atossa Therapeutics Driven by Strategic Focus on Z-endoxifen and Strong Financial Position
- Biotech Alert: Searches spiking for these stocks today